Abstract
Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive oxygen species (ROS). Here we show that cardiomyocyte-specific deletion of Top2b (encoding topoisomerase-IIβ) protects cardiomyocytes from doxorubicin-induced DNA double-strand breaks and transcriptome changes that are responsible for defective mitochondrial biogenesis and ROS formation. Furthermore, cardiomyocyte-specific deletion of Top2b protects mice from the development of doxorubicin-induced progressive heart failure, suggesting that doxorubicin-induced cardiotoxicity is mediated by topoisomerase-IIβ in cardiomyocytes.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
FUNDC1 protects against doxorubicin-induced cardiomyocyte PANoptosis through stabilizing mtDNA via interaction with TUFM
Cell Death & Disease Open Access 05 December 2022
-
A non-coding GWAS variant impacts anthracycline-induced cardiotoxic phenotypes in human iPSC-derived cardiomyocytes
Nature Communications Open Access 22 November 2022
-
Integrated multi-omics analysis of adverse cardiac remodeling and metabolic inflexibility upon ErbB2 and ERRα deficiency
Communications Biology Open Access 12 September 2022
Access options
Subscribe to Journal
Get full journal access for 1 year
$79.00
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.


Accession codes
References
Yeh, E.T. & Bickford, C.L. J. Am. Coll. Cardiol. 53, 2231–2247 (2009).
Force, T. & Kolaja, K.L. Nat. Rev. Drug Discov. 10, 111–126 (2011).
Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D. & Liu, L.F. Science 226, 466–468 (1984).
Capranico, G., Tinelli, S., Austin, C.A., Fisher, M.L. & Zunino, F. Biochim. Biophys. Acta 1132, 43–48 (1992).
Lyu, Y.L. et al. Mol. Cell. Biol. 26, 7929–7941 (2006).
Singal, P.K. & Iliskovic, N. N. Engl. J. Med. 339, 900–905 (1998).
Myers, C. et al. Semin. Oncol. 10, 53–55 (1983).
Martin, E. et al. Toxicology 255, 72–79 (2009).
Lyu, Y.L. et al. Cancer Res. 67, 8839–8846 (2007).
Lyu, Y.L. & Wang, J.C. Proc. Natl. Acad. Sci. USA 100, 7123–7128 (2003).
Sohal, D.S. et al. Circ. Res. 89, 20–25 (2001).
Okamura, S. et al. Mol. Cell 8, 85–94 (2001).
Ogasawara, J. et al. Nature 364, 806–809 (1993).
Plesca, D., Mazumder, S. & Almasan, A. Methods Enzymol. 446, 107–122 (2008).
Arany, Z. et al. Proc. Natl. Acad. Sci. USA 103, 10086–10091 (2006).
Lai, L. et al. Genes Dev. 22, 1948–1961 (2008).
Wang, J. et al. Circ. Res. 106, 1904–1911 (2010).
Wallace, K.B. Pharmacol. Toxicol. 93, 105–115 (2003).
Sahin, E. et al. Nature 470, 359–365 (2011).
Ju, B.G. et al. Science 312, 1798–1802 (2006).
Liao, R. & Jain, M. Methods Mol. Med. 139, 251–262 (2007).
Bawa-Khalfe, T., Cheng, J., Wang, Z. & Yeh, E.T. J. Biol. Chem. 282, 37341–37349 (2007).
Ishii, K.A. et al. Nat. Med. 15, 259–266 (2009).
Zeisberg, E.M. et al. Nat. Med. 13, 952–961 (2007).
Acknowledgements
We thank C.H. Ren for expert technical assistance and F.M. Lin and H. Dou for conducting studies on mitochondria DNA. W.C. Claycomb (Louisiana State University Health Science Center) provided HL-1 cells. This study is supported by the Cancer Prevention Research Institute of Texas and McNair Medical Institute (E.T.H.Y.), US National Institutes of Health grant CA102463 (to L.F.L.), the New Jersey Commission on Cancer Research Grant 06-2419-CCR-EO, US Department of Defense Idea Award W81XWH-07-1-0407 and Concept Award W81XWH06-1-0514 (to Y.L.L.).
Author information
Authors and Affiliations
Contributions
E.T.H.Y. and L.F.L. conceived the project. S.Z., X.L., T.B.-K., L.-S.L. and Y.L.L. performed experiments and data analysis. E.T.H.Y. and S.Z. wrote the manuscript with editorial input from L.F.L. and Y.L.L.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–5 and Supplementary Tables 1 and 2 (PDF 896 kb)
Rights and permissions
About this article
Cite this article
Zhang, S., Liu, X., Bawa-Khalfe, T. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18, 1639–1642 (2012). https://doi.org/10.1038/nm.2919
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2919
This article is cited by
-
Major vault protein attenuates cardiomyocyte injury in doxorubicin-induced cardiomyopathy through activating AKT
BMC Cardiovascular Disorders (2022)
-
Cardioprotective effects of sodium thiosulfate against doxorubicin-induced cardiotoxicity in male rats
BMC Pharmacology and Toxicology (2022)
-
Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?
Lipids in Health and Disease (2022)
-
Promising anti-leukemic effect of Zataria multiflora extract in combination with doxorubicin to combat acute lymphoblastic leukemia cells (Nalm-6) (in vitro and in silico)
Scientific Reports (2022)
-
FUNDC1 protects against doxorubicin-induced cardiomyocyte PANoptosis through stabilizing mtDNA via interaction with TUFM
Cell Death & Disease (2022)